BC Week In Review | Aug 8, 2016
Clinical News

AQU-005: Phase I started

NeuroMax began an open-label, Russian Phase I trial to evaluate AQU-005 in 24 healthy volunteers. NeuroMax plans to begin proof-of-concept (POC) trials of the product in patients with neuropathic pain in 4Q16. NeuroMax has worldwide...
Items per page:
1 - 1 of 1